Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain.

PubWeight™: 0.84‹?›

🔗 View Article (PMC 190908)

Published in J Virol on November 01, 1996

Authors

M Girard1, L Yue, F Barré-Sinoussi, E van der Ryst, B Meignier, E Muchmore, P N Fultz

Author Affiliations

1: Institut Pasteur, Paris, France.

Articles cited by this

Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol (1990) 6.73

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (1990) 5.33

Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet (1993) 3.28

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 3.22

Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol (1996) 3.04

A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol (1994) 2.88

Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J Virol (1986) 2.65

Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol (1995) 2.48

Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol (1996) 2.45

Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol (1994) 2.36

Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol (1994) 2.29

Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. AIDS Res Hum Retroviruses (1993) 2.22

Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden. Virology (1995) 2.07

Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I. J Virol (1995) 1.98

Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science (1992) 1.71

Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology (1994) 1.46

Genetic and phylogenetic analysis of env subtypes G and H in central Africa. AIDS Res Hum Retroviruses (1994) 1.34

HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine (1994) 1.31

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol (1995) 1.25

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis (1996) 1.20

HIV-1 sequence subtype D in the United States. AIDS Res Hum Retroviruses (1994) 1.00

Articles by these authors

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61

Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science (1984) 10.38

Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med (1998) 4.92

HIV-1 reverse transcriptase specifically interacts with the anticodon domain of its cognate primer tRNA. EMBO J (1989) 4.73

A prokaryotic voltage-gated sodium channel. Science (2001) 4.56

Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. J Mol Biol (1990) 4.38

TRP-PLIK, a bifunctional protein with kinase and ion channel activities. Science (2001) 4.33

Herpes simplex virus 1 mutant deleted in the alpha 22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice. J Virol (1985) 4.17

Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature (1992) 4.11

Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines. Science (1984) 4.02

The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol (1996) 3.82

Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci U S A (1986) 3.76

Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol (1994) 3.70

A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol (1998) 3.65

HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med (1998) 3.61

Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature (1990) 3.54

The Drosophila fusome, a germline-specific organelle, contains membrane skeletal proteins and functions in cyst formation. Development (1994) 3.40

NYVAC: a highly attenuated strain of vaccinia virus. Virology (1992) 3.38

Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Lancet (1985) 3.27

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 3.22

Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A (1995) 3.20

Mosaic genome structure of simian immunodeficiency virus from west African green monkeys. EMBO J (1994) 3.19

Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature (1987) 2.82

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther (2007) 2.80

Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J Virol (1986) 2.65

Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res (1996) 2.50

Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology (1985) 2.23

Molecular cloning of lymphadenopathy-associated virus. Nature (1985) 2.22

Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. AIDS Res Hum Retroviruses (1993) 2.22

Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A (1994) 2.21

Inactivation of lymphadenopathy associated virus by chemical disinfectants. Lancet (1984) 2.19

Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol (1996) 2.12

Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 2.09

Spectrum of disease in macaque monkeys chronically infected with SIV/SMM. Vet Immunol Immunopathol (1989) 2.09

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine (2000) 1.97

Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.97

Wild Mandrillus sphinx are carriers of two types of lentivirus. J Virol (2001) 1.96

Prevalence of antibodies to lymphadenopathy-associated retrovirus in African patients with AIDS. Science (1984) 1.95

High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol (1993) 1.93

Transmural heterogeneity of action potentials and Ito1 in myocytes isolated from the human right ventricle. Am J Physiol (1998) 1.92

Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev (1997) 1.88

Nucleotide sequence of HIV1-NDK: a highly cytopathic strain of the human immunodeficiency virus. Gene (1989) 1.83

A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. Virology (1993) 1.83

Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res (1986) 1.83

Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res Hum Retroviruses (2001) 1.77

Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in patients with AIDS. Science (1984) 1.73

A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J Virol (1994) 1.72

The natural history of infection with the lymphadenopathy-associated virus/human T-lymphotropic virus type III. Ann Intern Med (1985) 1.71

Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science (1992) 1.71

A distinct African lentivirus from Sykes' monkeys. J Virol (1993) 1.58

Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol (1993) 1.57

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses (1995) 1.56

Lymphadenopathy-associated viral antibody in AIDS. Immune correlations and definition of a carrier state. N Engl J Med (1984) 1.51

Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation (1998) 1.50

Should South Africa be preparing for HIV-1 vaccine efficacy trials? S Afr Med J (1997) 1.40

Detection of widespread hepatocyte infection in chronic hepatitis C. Hepatology (1998) 1.39

Components of saliva inactivate human immunodeficiency virus. Lancet (1986) 1.39

African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol (1996) 1.39

Vaginal transmission of human immunodeficiency virus (HIV) to a chimpanzee. J Infect Dis (1986) 1.38

Myelopathy in a patient dually infected with HIV-1 and HTLV-I. S Afr Med J (1992) 1.38

Isolation from African Sykes' monkeys (Cercopithecus mitis) of a lentivirus related to human and simian immunodeficiency viruses. J Virol (1991) 1.38

Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (1992) 1.36

Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur J Biochem (1990) 1.33

Serological and virological characterization of HIV-1 group O infection in Cameroon. AIDS (1997) 1.33

Basic mechanisms of atrial fibrillation--very new insights into very old ideas. Annu Rev Physiol (2000) 1.31

SIV from stump-tailed macaques: molecular characterization of a highly transmissible primate lentivirus. Virology (1992) 1.29

Viral load in tissues during the early and chronic phase of non-pathogenic SIVagm infection. J Med Primatol (2004) 1.29

Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection. AIDS Res Hum Retroviruses (1992) 1.28

Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J Infect Dis (1995) 1.26

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol (1995) 1.25

Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. Circ Res (1998) 1.24

Wild-type isopropylmalate isomerase in Salmonella typhimurium is composed of two different subunits. J Bacteriol (1981) 1.24

Cell-to-cell contact results in a selective translocation of maternal human immunodeficiency virus type 1 quasispecies across a trophoblastic barrier by both transcytosis and infection. J Virol (2001) 1.21

Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with anti-retroviral drugs in France. Clin Exp Immunol (2007) 1.19

Cadmium exposure and health effects among residents in an irrigation area with ore dressing wastewater. Sci Total Environ (1990) 1.18

Establishment of latency in mice by herpes simplex virus 1 recombinants that carry insertions affecting regulation of the thymidine kinase gene. J Virol (1985) 1.17

Rift Valley fever virus: a seroepidemiologic study of small terrestrial vertebrates in South Africa. Am J Trop Med Hyg (1997) 1.17

Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. AIDS Res Hum Retroviruses (1992) 1.17

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine (1995) 1.15

Early pathogenesis of disease caused by SIVsmmPBj14 molecular clone 1.9 in macaques. AIDS Res Hum Retroviruses (1993) 1.14

Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs : potential relevance to ionic mechanisms in vivo. Circulation (2000) 1.12

HIV-1 group N among HIV-1-seropositive individuals in Cameroon. AIDS (2000) 1.12

A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. J Virol (1991) 1.12

Transmission of lymphadenopathy-associated virus/human T lymphotropic virus type III in sexual partners. Seropositivity does not predict infectivity in all cases. Am J Med (1986) 1.11

The evolutionary rate of nonpathogenic simian immunodeficiency virus (SIVagm) is in agreement with a rapid and continuous replication in vivo. Virology (1996) 1.11

Detection and titration of neutralizing antibodies to HIV using an inhibition of the cytopathic effect of the virus on MT4 cells. J Virol Methods (1987) 1.11

Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice. Vaccine (1992) 1.10

Mucosal immune system of the human genital tract. J Infect Dis (1999) 1.10

Selection of maternal human immunodeficiency virus type 1 variants in human placenta. European Network for In Utero Transmission of HIV-1. J Infect Dis (1999) 1.09

Allelic frequencies of host genetic variants influencing susceptibility to HIV-1 infection and disease in South African populations. AIDS (2000) 1.09

Chronic hepatitis in chimpanzee carriers of hepatitis B virus: morphologic, immunologic, and viral DNA studies. Proc Natl Acad Sci U S A (1980) 1.07

Genetic differences accounting for evolution and pathogenicity of simian immunodeficiency virus from a sooty mangabey monkey after cross-species transmission to a pig-tailed macaque. J Virol (1992) 1.06

A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res (2001) 1.06

A "sentinel" technique for monitoring viral aerosol contamination. J Infect Dis (1991) 1.06

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses (1999) 1.05